suggested as a marker of rejection episodes after organ transplantation. To evaluate the analytical performance of a "sandwich-type" enzyme immunoassay method for sIL-2R and to verify whether increased concentrations of sIL-2R might be a useful marker of allograft rejection, we quantified sIL-2R in serum samples from heart-or kidney-transplant patients. The mean (±SD) pre-transplant value of slL-2R (592 ± 209 kiio-units/L) in heart-transplant patients was significantly higher (P <0.01) than that observed in controls (350 ± 101 kilo-units/L). After heart transplantation, the concentrations of siL-2R slowly decreased to baseline in successfully treated patients but increased significantly (1129 ± 215 kilo-units/L; P <0.01) during acute rejection crisis. However, severe infections were also associated with a significant increase of sIL-2R, so the sIL-2R test is not specific for allograft rejection. The mean pre-transpiant concentration of slL-2R was also increased (1943 ± 878 kilounits/L) in 26 renal-transplant patients; after transplantation, this value returned to normal, as did that for creatinine, but persisted steadily high in five patients who experienced acute tubular necrosis. In this group of patients, the slL-2R concentration increased by 1.5-to fourfold, both during acute rejection episodes and in clinically evident infection; thus measurement of creatinine and siL-2R concentrations can help to distinguish between rejection, infection, and cyclosporine toxicity. In two episodes of mild cyclosponne-induced nephrotoxicity, we observed slight increases in serum creatmine (which returned to baseline when the cyclosporine dose was decreased) not associated with an increase in slL-2R. We conclude that systematic monitoring of slL-2R together with other biochemical and clinical markers may be useful in the management of kidney-transplant patients.
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Additional Keyphrases: creatinine cyclosporine -nephrotoxicity Interleukin 2 (IL-2), a T-cell growth factor, is synthesized and secreted after activation with antigen or mitogen in the presence of the monokine interleukin 1 (1, 2) . The activation of T-lymphocytes is accompanied by expression of specific high-affinity membrane receptors for IL-2 (IL-'Istituto di Fisiologia Climca del C.N.R., and 2Inituth di Patologia Chirurgica 2, Universit#{226} di Pisa, via Saw 8,56100 Pisa, Italy.
Ospedale Ca Granda, Milano, Italy. 4Nonstandard abbreviations: IL-2, interleukin 2; sIL-2R, soluble receptor for IL-2; and CsA, cyclosporine.
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in fact, in kidney-transplant recipients, sIL-2R greatly increased during rejection or viral infections, whereas patients with CsA nephrotoxicity had sIL-2R concentrations significantly below those of patients with rejection (11). Moreover, two preliminary reports suggest that an increase of sIL-2R in heart-, heart-lung-, or liver-transplant recipients may be associated with a worse prognosis (12) and that the determination of sJL-2R concentrations may prove useful in monitoring cardiac allograft rejection (13).
To evaluate the analytical performances of a "sandwichtype" enzyme immunoassay method for measuring sIL-2R and to veriI' whether increased concentrations of circulating sIL-2R may be considered a useful marker of allograft rejection, we assayed sIL-2R concentrations in serum samples of heart-or kidney-transplant patients.
Materials and Methods

sJL-2R assay.
The sIL-2R concentration was assayed by a sandwich enzyme immunoassay method (T Cell Science, Inc., Cambridge, MA 02139) that involves two different anti-IL-2R monoclonal antibodies; the firstone is adsorbed onto polystyrene microtiter wells and the other is conjugated with horseradish peroxidase (EC 1.11.1.7). Soluble IL-2R present in the serum sample binds to antibody on the well and, after washing of the unreacted materials, the enzyme conjugated to the anti-IL-2R antibody is added to complete the sandwich. The unbound enzyme-conjugated antibody is then removed and a substrate solution (hydro-
is added to form a colored product (measured at 490 nm), the quantity of which is proportional to the amount of sIL-2R present in the sample. The concentration of unknown samples is estimated by interpolation on a calibration curve prepared with five sIL-2R standards. sIL-2R concentration is expressed in kilo-units per liter, 1 kilo-unit being defined as the amount of sIL-2R released or present in 1 mL of a standardpreparation of cell-culture supernatant fluid from sensitivity (lowest detection limit) was 53 ± 20 kilophytohemagglutinin-stimulated peripheral blood cells (T urnts/L. The between-assay variability (CV), as assessed by Cell Science, Inc.). The mean precision profile was cumulatively computed measuring (in eight runs) three serum pools containing different amounts of sIL-2R (349 ± 37, 628 ± 66, or 989 ± from 10 assays, by use of a previously described computer program (14, 15) ; the sensitivity (lowest detection limit) was read on the precision proffle as the lowest concentration distinguishable from zero (confidence limit ±2 SD) or the concentration corresponding to a CV of 50%; the working range, also derived from the precision proffle, was the concentration range measurable with a within-assay precision (CV) <10%. The concentration of CsA in blood samples was measured by fluorescence polarization immunoassay (TDx; Abbott Labs., N. Chicago, IL), as previously reported (16) .
Healthy subjects. We studied 38 adult blood donors (26 men and 12 women, ages 18-60 years).
Heart failure and transplantation. We studied 13 hearttransplant patients: six who developed a biopsy-proven episode of acute rejection that was successfully treated with supplementary immunosuppression, five with a severe nonviral infection, and two others with acute viral infections. All these patients were receiving standard therapy with CsA and steroids. A baseline value for sIL-2R was established for each patient in a clinically and instrumentally determined rejection-free and infection-free interval, These heart rejection episodes were graded histologically as moderate, according to Billingham (17) . The patients underwent routine endomyocardial biopsy weekly in the firstmonth, every two weeks for the second and third month, once every month thereafter until the sixthmonth, and whenever clinically indicated. Supplementary treatment with pulsatile steroids (1 g of methylprednisolone intravenously or 100 mg of oral prednisone for three days) was administered for moderate rejection or mild rejection plus clinical finding of heart failure. Persistent rejection afterthis therapy with steroids was treatedwith horse anti-lymphocyte globulin (20 mg/kg of body wt, intravenously, for 10 days).
Kidney end-stage disease and transplantation.
We studied 39 patients (27 men and 12 women, ages 32-76 years) with end-stage renal disease who had been treated by hemodialysis for from six months to 22 years; 35% of them 102 kilo-units/L) was 10.7%, 10.5%, and 10.3%, respectively. Serial sample dilution (parallelism test) showed a linear relationship (r = 0.999) with dilution.
Control subjects. The mean (± SD) sIL-2R concentration in 38 healthy subjects was 350 ± 101 kilo-unitsfL (range 165-630 kilo-unitsfL), without any significant difference between men and women.
Heart -transplant patients.
The mean pre-operative value of sIL-2R (592 ± 209 kilo-unitsfL) found in 13 hearttransplant patients was significantly (P <0.01) higher than that observed in controls. In six transplant patients, sIL-2R increased significantly over the baseline values (1129 ± 215 kilo-unitsfL, P <0.01 by paired t-test) during acute rejection crisis documented by clinical findings and myocardial biopsy; these increases were significantly reduced baseline aftersuccessful treatment (544 ± 395 kilounits/Li, p <0.01). Moreover, we observed that severe bac- treatment. The concentration of IL-2R at the beginning of acute rejection showed a 1.5-to fourfold increase. Moreover, we observed that in five infection episodes (including two cases of interstitial pneumonias) sIL-2R was increased up to sixfold. Figure 2 shows the time-course of sIL-2R in a patient who experienced an episode of acute rejection (reversed by treatment) and two episodes of viral infection. During the rejection episode, the concentrations of sIL-2R and creatinine simultaneously increased, whereas the infections produced an increase of sIL-2R only, with no change of serum creatiine.
Two episodes of mild CsA nephrotoxicity were observed; in these patients only a slight increment of serum creatinine (which returned to baseline when the CsA dose was decreased) was found, whereas the sIL-2R was unaffected. Table 1 reports concentrations of CsA, sIL-2R, and creatinine in one of these two patients.
Discussion
We found the enzyme imniunoassay technique used in the present study to be suitable and reliable for the measurement of sIL-2R concentration in transplant patients.
Our results indicate that sIL-2R concentrations increase to the same extent both during allograft rejection and infection episodes in heart-or kidney-transplant patients; therefore, the sIL-2R test is nonspecific and cannot distinguish rejection from infection. However, in renal transplant, rejection produces a characteristic pattern, i.e., a parallel increase in both creatinine and sIL-2R. Moreover, we were able to observe in these patients two episodes of mild CsA nephrotoxicity in which creatimne (and CsA) increased while sJL-2R remained steady. These data confirm the CsA nephrotoxicityepisode documented by the slight increase in serum creatinine concomitantly with a doubling of the CsA blood concentration. Two to three weeksafter, when theCsA dose was decreased, the concentrations of CsA and creatinine returned totheir normalranges. The concentrations of sIL-2R declined progressivelyand continuously throughoutthis period, reaching the normal rangeone month after transplantation.
findings of Colvin et al. (11) , who suggested that sIL-2R measurement may be useful in distinguishing between
CsA nephrotoxicity, rejection, and viral infection. In the rejection episodes, however, the concomitant increase of sIL-2R and creatinine suggest that the sIL-2R test is not more sensitive than the creatinine assay.
We conclude that systematic monitoring of sIL-2R as well as other biochemical and clinical markers can be a useful tool in managing kidney-transplant patients.
